CD274 and neoplasm: Prospective research is needed to further assess any immune tumor biology and ICI treatment benefit differences of plasma PD-L1 RNA and tissue PD-L1 protein levels of expression to provide insight into the full potential clinical utility of plasma PD-L1 testing.